ArticleGut2022

Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.

Sumit Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.